📊 VRDN Key Takeaways
Is Viridian Therapeutics, Inc.\DE (VRDN) a Good Investment?
Viridian Therapeutics is a development-stage pharmaceutical company burning $119.7M quarterly with only $141K in revenue, indicating zero commercial product traction. While the $176.3M cash position and 0.03x debt/equity provide a financial buffer of approximately 14-15 quarters, the company faces existential risk absent successful pipeline monetization. No clear path to profitability is evident from current fundamentals.
Viridian Therapeutics, Inc.\DE Key Strengths (VRDN)
- $176.3M in cash equivalents provides substantial operational runway at current burn rate
- Fortress balance sheet with low leverage (0.03x debt/equity) and $636M stockholders' equity
- Excellent liquidity ratios (15.15x current/quick) enable flexibility for strategic funding or partnerships
VRDN Stock Risks: Viridian Therapeutics, Inc.\DE Investment Risks
- Unsustainable quarterly cash burn of -$119.7M against near-zero revenue represents critical solvency risk
- Pre-commercial stage evidenced by $141K revenue indicates failed or delayed pipeline commercialization
- Approximately 1.5-year cash runway until depletion absent revenue growth or additional capital raises; high biotech execution risk
Key Metrics to Watch
- Quarterly revenue growth and product launch timeline
- Operating cash flow trends and cash balance trajectory
- Regulatory milestones, clinical trial data, and pipeline advancement
Viridian Therapeutics, Inc.\DE (VRDN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 15.15x current ratio provides a solid financial cushion.
VRDN Profit Margin, ROE & Profitability Analysis
VRDN vs Healthcare Sector: How Viridian Therapeutics, Inc.\DE Compares
How Viridian Therapeutics, Inc.\DE compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Viridian Therapeutics, Inc.\DE Stock Overvalued? VRDN Valuation Analysis 2026
Based on fundamental analysis, Viridian Therapeutics, Inc.\DE has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Viridian Therapeutics, Inc.\DE Balance Sheet: VRDN Debt, Cash & Liquidity
VRDN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Viridian Therapeutics, Inc.\DE's revenue has grown significantly by 2,291% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6.66 indicates the company is currently unprofitable.
VRDN Revenue Growth, EPS Growth & YoY Performance
VRDN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $72.0K | -$86.9M | N/A |
| Q3 2025 | $86.0K | -$34.6M | N/A |
| Q2 2025 | $72.0K | -$48.5M | N/A |
| Q1 2025 | $72.0K | -$48.5M | N/A |
| Q3 2024 | $72.0K | -$47.7M | $-1.09 |
| Q2 2024 | $72.0K | -$48.5M | $-1.02 |
| Q1 2024 | $72.0K | -$48.5M | $-0.79 |
| Q3 2023 | $72.0K | -$25.7M | $-0.86 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Viridian Therapeutics, Inc.\DE Dividends, Buybacks & Capital Allocation
VRDN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Viridian Therapeutics, Inc.\DE (CIK: 0001590750)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VRDN
What is the AI rating for VRDN?
Viridian Therapeutics, Inc.\DE (VRDN) has an AI grade of D with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VRDN's key strengths?
Claude: $176.3M in cash equivalents provides substantial operational runway at current burn rate. Fortress balance sheet with low leverage (0.03x debt/equity) and $636M stockholders' equity.
What are the risks of investing in VRDN?
Claude: Unsustainable quarterly cash burn of -$119.7M against near-zero revenue represents critical solvency risk. Pre-commercial stage evidenced by $141K revenue indicates failed or delayed pipeline commercialization.
What is VRDN's revenue and growth?
Viridian Therapeutics, Inc.\DE reported revenue of $141.0K.
Does VRDN pay dividends?
Viridian Therapeutics, Inc.\DE does not currently pay dividends.
Where can I find VRDN SEC filings?
Official SEC filings for Viridian Therapeutics, Inc.\DE (CIK: 0001590750) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VRDN's EPS?
Viridian Therapeutics, Inc.\DE has a diluted EPS of $-2.98.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VRDN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Viridian Therapeutics, Inc.\DE has a D grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VRDN stock overvalued or undervalued?
Valuation metrics for VRDN: ROE of -16.5% (sector avg: 15%), net margin of -74,397.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VRDN's AI grade for 2026?
Our dual AI analysis gives Viridian Therapeutics, Inc.\DE a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VRDN's free cash flow?
Viridian Therapeutics, Inc.\DE's operating cash flow is $-119.7M, with capital expenditures of $23.0K. FCF margin is -84,877.3%.
How does VRDN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -74,397.9% (avg: 12%), ROE -16.5% (avg: 15%), current ratio 15.15 (avg: 2).